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Abstract. 
 
In nutrient-rich, vegetative conditions, the 
yeast 
 
Saccharomyces cerevisiae
 
 transports a resident 
 
protease, aminopeptidase I (API), to the vacuole by 
 
the cytoplasm to vacuole targeting (Cvt) pathway, 
thus contributing to the degradative capacity of this 
organelle. When cells subsequently encounter starva-
tion conditions, the machinery that recruited precursor 
API (prAPI) also sequesters bulk cytosol for delivery, 
breakdown, and recycling in the vacuole by the au-
tophagy pathway. Each of these overlapping alternative 
transport pathways is speciﬁcally mobilized depending 
on environmental cues. The basic mechanism of cargo 
packaging and delivery involves the formation of a 
double-membrane transport vesicle around prAPI 
and/or bulk cytosol. Upon completion, these Cvt and 
autophagic vesicles are targeted to the vacuole to al-
low delivery of their lumenal contents.
Key questions remain regarding the origin and for-
mation of the transport vesicle. In this study, we have 
cloned the 
 
APG9/CVT7
 
 gene and characterized the 
gene product. Apg9p/Cvt7p is the ﬁrst characterized in-
tegral membrane protein required for Cvt and autoph-
agy transport. Biochemical and morphological analyses 
indicate that Apg9p/Cvt7p is localized to large perivac-
uolar punctate structures, but does not colocalize with 
typical endomembrane marker proteins. Finally, we 
have isolated a temperature conditional allele of 
 
APG9
 
/
 
CVT7
 
 and demonstrate the direct role of 
Apg9p/Cvt7p in the formation of the Cvt and au-
tophagic vesicles. From these results, we propose that 
Apg9p/Cvt7p may serve as a marker for a specialized 
compartment essential for these vesicle-mediated alter-
 
native targeting
 
 
 
pathways.
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Introduction
 
To survive periods of starvation such as serum deprivation
(Kadowaki et al., 1996; Mortimore et al., 1996; Blommaart
et al., 1997) and carbon and nitrogen starvation (Take-
shige et al., 1992), the autophagy pathway delivers non-
essential cytoplasmic material, including proteins and or-
ganelles, to the vacuole/lysosome for subsequent digestion
by resident hydrolases. The breakdown products are then
recycled for various essential metabolic processes. In 
 
Sac-
charomyces cerevisiae
 
, there is a genetic overlap between
autophagy mutants (
 
apg
 
 and 
 
aut
 
; Tsukada and Ohsumi,
1993; Thumm et al., 1994) and mutants in the biosynthetic
cytoplasm to vacuole targeting (Cvt)
 
1
 
 pathway (Harding et
al., 1996; Scott et al., 1996) indicating that these two pro-
cesses are mechanistically similar.
In both pathways, mechanisms of cargo selection, trans-
port vesicle formation, topology, and subsequent fusion
and cargo release possess features that diverge from the
classical tenets of vesicle transport through the secretory
pathway. The Cvt pathway cargo protein, aminopeptidase
I (API), is synthesized in the cytosol as a precursor en-
zyme (prAPI) and assembled into a higher-ordered struc-
ture called the Cvt complex (Fig. 1; Baba et al., 1997; Kim
et al., 1997; Scott et al., 1997). Electron micrographs show
the Cvt complex to be an electron-dense structure devoid
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dase H; GFP, green fluorescent protein; ORF, open reading frame; PGK,
phosphoglycerate kinase; prAPI, precursor API. 
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of cytosol (Baba et al., 1997; Scott et al., 1997). Under star-
vation conditions, prAPI is transported to the vacuole via
autophagy. The cargo in autophagy, however, includes not
only prAPI in the form of the Cvt complex, but also bulk
cytosolic proteins and organelles. While the recruitment of
bulk cytosol in autophagy is generally nonselective, spe-
cific degradation of targeted organelles such as peroxi-
somes has also been reported (Tuttle and Dunn, 1995; Sa-
kai et al., 1998; reviewed in Klionsky and Ohsumi, 1999).
EM has been used to follow the sequestration process of
the Cvt pathway and autophagy, and has revealed mem-
brane structures that enwrap the Cvt complex or bulk cy-
tosol (Fig. 1; Baba et al., 1994, 1997). The completion of
the cargo sequestration event results in the formation of
the double-membrane Cvt vesicle (130–150 nm in diame-
ter; Baba et al., 1997; Scott et al., 1997) or autophagosome
(300–900 nm in diameter; Baba et al., 1994). Therefore,
compared with a typical secretory transport vesicle of 50–
100 nm in diameter, a Cvt vesicle can range from 2–27
times bigger in volume, and an autophagosome can be
 
.
 
1,000 times as large.
The fusion of the Cvt and autophagic vesicles with the
vacuole requires general vesicle fusion machinery, includ-
ing the vacuolar target-SNARE (soluble N-ethylmale-
imide sensitive fusion protein attachment protein recep-
tor) Vam3p (Darsow et al., 1997; Sato et al., 1998) and the
rab GTPase Ypt7p (Kim et al., 1999; Kirisako et al., 1999;
George et al., 2000). Fusion of Cvt vesicles with the vacu-
ole requires the vesicle-SNARE Vti1p (Fischer von Mol-
lard and Stevens, 1999) and Vps18p (Scott et al., 1997). In
addition, Cvt and autophagic vesicle fusion with the vacu-
ole releases the inner vesicle (the Cvt or autophagic body)
into the lumen. Maturation of prAPI and the degradation
of cytosolic contents occur only after inner-vesicle break-
down. Strains defective in the vacuolar hydrolases protein-
ase A or B accumulate Cvt and autophagic bodies and are
not able to mature prAPI (Klionsky et al., 1992; Takeshige
et al., 1992). In addition, Cvt17p and/or proper vacuolar
pH are required for Cvt and autophagic body breakdown,
respectively (Nakamura et al., 1997; Scott et al., 1997).
A key issue that remains to be resolved is the identity of
the donor compartment from which the Cvt and auto-
phagosomal membranes are derived. Immunocytochemical
studies in mammalian cells have suggested that ribo-
some-free regions of the ER provide the source mem-
brane for the autophagosome (Dunn, 1990; Tooze et al.,
1990; Yokota et al., 1993). However, others have postu-
lated that since the autophagosomal membrane does not
resemble any known subcellular compartment, the origin
of this enwrapping membrane must be derived from an
equally specialized donor compartment, termed the
phagophore (Seglen et al., 1996; Stromhaug et al., 1998).
These and other conflicting studies demonstrate the need
for a genetically tractable system in which to address this
question. To that end, the autophagy/Cvt mutants from
 
S. cerevisiae
 
 may serve as a simpler model system.
Analyses of the 
 
cvt
 
, 
 
apg
 
, and 
 
aut
 
 mutants have revealed
defects at various stages of the Cvt and autophagy path-
ways. Cloning of the genes and characterization of the
gene products have identified a growing number of com-
Figure 1. Model of Cvt and
autophagy transport to the
vacuole. There are many
shared mechanistic features
for the two pathways. 1, Cvt
complex formation: prAPI is
synthesized in the cytosol,
oligomerizes into a dodeca-
mer, and assembles into a
Cvt complex; 2, double-mem-
brane vesicle formation: the
Cvt complex is enwrapped by
a membrane source which,
upon expansion and comple-
tion, forms the double-mem-
braned Cvt vesicle (Cvt path-
way) or autophagosome
(autophagy); 3, vesicle target-
ing to the vacuole: the dou-
ble-membrane vesicle is then
targeted to the vacuole fol-
lowed by fusion with the vac-
uolar membrane and release
of the inner vesicle, termed the Cvt body (Cvt pathway) or the autophagic body (autophagy), into the vacuolar lumen. Subsequent
breakdown of the Cvt or autophagic body releases prAPI into the lumen where it is proteolytically processed, in a proteinase A-depen-
dent manner, to mature API. Major differences between the pathways include the following: 1, cargo selectivity: the Cvt pathway is a se-
lective process and the Cvt vesicles appear to exclude bulk cytosolic components as cargo. In contrast, autophagy is nonselective and au-
tophagosomes carry bulk cytosol, in addition to the Cvt complex, to the vacuole. prAPI is transported via both vesicle types. A
recombinant, cytosolic marker protein, Pho8D60p, is transported to the vacuole via autophagy. Delivery of Pho8D60p to the vacuole
can be monitored through cleavage of the COOH-terminal propeptide. 2, Vesicle size: Cvt vesicles are z150 nm in diameter, whereas
autophagosomes are 300–900 nm in diameter. 3, Conditions for induction: the Cvt pathway is active in vegetative growth conditions
while autophagy is induced under starvation conditions. 
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ponents required for these pathways, including regulatory
kinases (Matsuura et al., 1997; Noda and Ohsumi, 1998),
members of an essential protein conjugation system (Mi-
zushima et al., 1998; Kim et al., 1999; Tanida et al., 1999;
Yuan et al., 1999; George et al., 2000), and vesicle-associ-
ated proteins (Lang et al., 1998; Kirisako et al., 1999;
Huang et al., 2000; for reviews see Klionsky and Ohsumi,
1999; Kim et al., 2000). However, all of these characterized
proteins are soluble or peripherally associated to mem-
branes. Therefore, they do not represent ideal markers for
the study of the subcellular compartments involved in the
Cvt and autophagy processes. Here, we report the cloning
and characterization of a novel protein, Apg9p/Cvt7p, the
first identified integral membrane protein of the Apg/Cvt
pathways. We show that Apg9p/Cvt7p does not colocalize
with known endomembrane markers and forms a promi-
nent, punctate structure proximal to the vacuole. Finally,
using a temperature-sensitive mutant of Apg9p, we dem-
onstrate its direct role in the vesicle formation step in the
autophagy and Cvt pathways.
 
Materials and Methods
 
Strains
 
The yeast strains used in this study are listed in Table I.
 
Antibodies
 
To prepare antiserum to Apg9p/Cvt7p, synthetic peptides corresponding
to amino acids 1–15 (National Institute for Basic Biology, Center for Ana-
lytical Instruments) or 74–89 and 138–156 (Multiple Peptide Systems)
were synthesized and conjugated individually to BSA or keyhole limpet
hemocyanin, respectively. Standard procedures were used to generate an-
tiserum in Japanese White or New Zealand White rabbits, respectively.
Antisera against API and carboxypeptidase Y (CPY) were prepared as
described previously (Klionsky et al., 1988, 1992). Antiserum against
phosphoglycerate kinase (PGK) was generously provided by Dr. Jeremy
Thorner (University of California, Berkeley, CA; Baum et al., 1978).
Anti-HA mAb 16B12 was from Berkeley Antibody Co., Inc. FITC-conju-
gated secondary anti-mouse antibody was from Roche Molecular Bio-
chemicals.
 
Materials
 
All restriction enzymes and Vent
 
R
 
 DNA polymerase were from New En-
gland Biolabs. AmpliTaq DNA polymerase was from Perkin Elmer Bio-
systems. Expre
 
35
 
S
 
35
 
S Protein Labeling Mix was from Dupont-New En-
gland Nuclear Research Products. Immobilon-P (polyvinylidene fluoride,
PVDF) was from Millipore. ConA Sepharose and Ficoll-400 were from
Pharmacia Biotech, Inc. Complete™ EDTA-free protease inhibitor cock-
tail and endoglycosidase H (endo H) were from Roche Molecular Bio-
chemicals. FM 4-64 dye was from Molecular Probes. Oxalyticase was from
Enzogenetics. YNB was from DifCo Laboratories, Inc. Zymolyase 100T
was from Seikagakukogyo. Oligonucleotides to pBR322 were from
Promega. All other oligonucleotides were synthesized by Operon Tech-
nologies, Inc. All other reagents were from Sigma Chemical Co. or Wako
Chemicals. 
 
Growth Media
 
Yeast cells were grown in rich medium (YPD; 1% yeast extract, 2% pep-
tone, and 2% glucose) or various synthetic minimal media. Synthetic min-
imal media with carbon and nitrogen sources were: SMD, 0.67% yeast ni-
trogen base, 2% glucose, and auxotrophic amino acids and vitamins as
needed; SD, 0.17% yeast nitrogen base without ammonium sulfate and
amino acids, 0.5% ammonium sulfate, and 2% glucose; or SCD, 0.17%
yeast nitrogen base without ammonium sulfate and amino acids, 0.5% am-
monium sulfate, 0.5% casamino acids and 2% glucose. Synthetic minimal
media lacking nitrogen and/or carbon sources were: SD(
 
2
 
N), 0.17% yeast
nitrogen base without ammonium sulfate and amino acids and 2% glu-
cose; and S(
 
2
 
N, 
 
2
 
C), 0.17% yeast nitrogen base without ammonium sul-
fate and amino acids.
 
Isolation of Mutants
 
The 
 
cvt
 
 mutants were isolated on the basis of prAPI accumulation (Hard-
ing et al., 1995, 1996). 
 
cvt7
 
 belongs in the group of mutants that share a ge-
netic overlap with mutants defective in autophagy, and is in the same com-
plementation group as 
 
aut9
 
 and 
 
apg9
 
 (Harding et al., 1996; Scott et al.,
1996). The 
 
cvt7-1
 
 mutant was used for subsequent analyses and cloning of
the 
 
CVT7
 
 gene as described below.
The Pho8
 
D
 
60p construct (Noda et al., 1995) was used to screen for ad-
ditional autophagy-defective mutants. Pho8
 
D
 
60p is an altered form of the
vacuolar hydrolase alkaline phosphatase lacking the NH
 
2
 
-terminal trans-
membrane domain. This modified protein is only delivered to the vacuole
through autophagy (Fig. 1). Proteolytic cleavage of the Pho8
 
D
 
60p propep-
tide in the vacuole lumen generates the active form of the enzyme. Yeast
strain TN124 expressing Pho8
 
D
 
60p was mutagenized with EMS and
spread onto YPD plates. Approximately 36,000 colonies were replica-
plated onto SD(
 
2
 
N) and incubated overnight at 30
 
8
 
C. 1% agar containing
0.1 mM 
 
a
 
-naphthyl phosphate, 1 mg/ml Fast Red TR salt, 5 mM MgCl
 
2
 
,
0.1 M Tris-HCl, pH 9.0, and 1 mM PMSF was melted and kept at 60
 
8
 
C.
Fast Red TR salt and PMSF were added to the melted agar, and 5 ml of
this mixture was poured onto the plate. Colonies that were able to carry
out autophagy and exhibited alkaline phosphatase activity turned brown.
The colonies that did not turn brown were picked from the master plate
and were subjected to a morphological observation of autophagy. Mutants
that did not accumulate intravacuolar vesicles upon starvation in the pres-
ence of PMSF (Tsukada and Ohsumi, 1993) were placed into complemen-
tation groups. The most abundant group was found to fit into the comple-
mentation group that was previously identified as 
 
apg9
 
 (Tsukada and
Ohsumi, 1993). The 
 
apg9-1
 
 mutant was chosen for further analysis.
 
Cloning of CVT7/APG9
 
The 
 
APG9/CVT7 
 
gene was independently cloned by our two laboratories.
Because 
 
.
 
99% of 
 
apg9/cvt7
 
 cells die after 6 d of nitrogen starvation, the
 
APG9/CVT7
 
 gene product is essential for cell viability under autophagy-
 
Table I. Yeast Strains Used in this Study
 
Strain Genotype Source or reference
 
CT83-1B
 
MATa leu2 trp1 ura3 pho8::pho8
 
D
 
60 apg9-1
 
This study
CTD1
 
MATa leu2 trp1 ura3 apg9
 
D
 
::TRP1
 
This study
JKY007
 
MAT
 
a
 
 his3-
 
D
 
200 leu2-3,112 lys2-801 trp1-
 
D
 
901 ura3-52 suc2-
 
D
 
9 GAL
 
 
 
apg9
 
D
 
::HIS3
 
This study
KSL12C
 
MAT
 
a
 
 leu2 trp1 ura3 vps4
 
D
 
::LEU2 pho8::pho8
 
D
 
60
 
This study
SEY6210
 
MAT
 
a
 
 his3-
 
D
 
200 leu2-3,112 lys2-801 trp1-
 
D
 
901 ura3-52 suc2-
 
D
 
9 GAL
 
Robinson et al., 1988
SKD6-1D
 
MATa leu2 trp1 ura3 apg6
 
D
 
::LEU2
 
Kametaka et al., 1998
THY154
 
MAT
 
a
 
 ade2-101 his3-
 
D
 
200 leu2-3,112 trp1-
 
D
 
901 ura3-52 suc2-
 
D
 
9 GAL cvt7-1
 
Harding et al., 1995
TK415
 
MATa leu2 ura3 ypt7
 
D
 
::LEU2 
 
Kirisako et al., 1999
STY1
 
MATa leu2 trp1 ura3 pep4
 
D
 
::URA3
 
 This  study
YW5-1B
 
MATa
 
 
 
ura3 trp1 leu2
 
  Noda et al., 1995 
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inducing conditions of nitrogen deprivation. Therefore, survival in nitro-
gen-poor medium offered a convenient selection strategy to clone 
 
APG9/
CVT7
 
. Specifically, strain THY154 (
 
cvt7-1
 
) and CT83-1B (
 
apg9-1
 
) cells
were transformed with a YCp50-based yeast genomic library (Rose et al.,
1987). Approximately 60,000 transformed colonies were then subjected to
nitrogen starvation for 6 d. Transformants that survived this regimen were
subjected to Western blot analysis. Transformants were isolated contain-
ing genomic plasmids that complemented the prAPI processing defect of
 
cvt7-1
 
 or the ability to accumulate autophagic bodies in 
 
apg9-1
 
. Partial
sequences from these genomic plasmids were entered into the 
 
Saccharo-
myces
 
 Genome Database (SGD; http://genome-www.stanford.edu/Sac-
charomyces/). The full-length sequences of these plasmids contained over-
lapping fragments of 7–8 kb. After further manipulations, the open
reading frame (ORF) of 
 
APG9/CVT7 
 
was identified as YDL149w. For
clarity, we will refer to the 
 
APG9/CVT7
 
 gene and the gene product as
 
APG9
 
 and Apg9p, respectively, henceforth in this section.
Using a NotI/BamHI digestion, an 
 
APG9 
 
cassette with 757 bp of up-
stream and 485-bp downstream sequences was subcloned into pRS414 and
pRS424, resulting in plasmids pAPG9(414) and pAPG9(424), respectively.
Both pAPG9(414) and pAPG9(424) complemented the prAPI processing
defect when transformed into the 
 
cvt7
 
 and 
 
apg9 
 
mutants. Similarly, a 4.8-kb
fragment containing a part of YCp50 cut with XbaI from plasmid p8001 en-
coding 
 
APG9
 
 was subcloned into pRS316 to generate plasmid p8007. This
plasmid was sufficient to suppress the autophagy defect of 
 
apg9
 
.
 
Disruption of the APG9 Chromosomal Locus
 
The chromosomal 
 
APG9 
 
locus was disrupted through two independent
approaches. First, a PCR-based strategy was employed to disrupt the
chromosomal copy of 
 
APG9
 
. The 
 
HIS3
 
 gene was PCR-amplified from the
pRS413 vector using oligonucleotides containing vector sequences outside
of the 
 
HIS3
 
 auxotrophic marker flanked by 
 
APG9
 
 sequences encoding
regions at the beginning and end of the 
 
APG9 
 
ORF: 5
 
9
 
-GAGA-
GAGATGAATACCAGTTACCCAACTCTCATGGGAAGTTGTAC-
TGAGAGTGCACCAT-3
 
9
 
 and 5
 
9
 
-GGATGATGTACACGACACAGT-
CTGCCTTATCTTCCGACGTCGGTATTTCACACCGCATA-3
 
9
 
. The
PCR product was transformed into strain SEY6210 wild-type cells and
grown on minimal plates lacking histidine. Transformants were then as-
sayed for API precursor accumulation. In addition, the 
 
apg9
 
D
 
 
 
strain was
crossed with the 
 
cvt7-1
 
 mutant, followed by tetrad analysis and Western
blotting with API antiserum. All of the germinants from 12 tetrads exhib-
ited a prAPI phenotype indicating that the 
 
APG9
 
 gene maps to the cor-
rect locus. The 
 
apg9
 
D
 
 strain was named JKY007.
In the second approach, plasmid p8007 was digested with EcoRI to re-
move a 700-bp fragment within the 
 
APG9
 
 ORF. An EcoRI fragment con-
taining the 
 
TRP1 
 
gene was ligated into the EcoRI sites of p8007 to gener-
ate p8009. Plasmid p8009 was digested with EcoT14I/SphI and a fragment
containing the 
 
TRP1
 
 marker and flanking 
 
APG9
 
 sequences was trans-
formed into YW5-1B wild-type cells. Disruption at the 
 
APG9
 
 locus was
confirmed by Southern blot. The 
 
apg9
 
D
 
 strain was crossed with the 
 
apg9-1
 
mutant. The resulting diploid retained an autophagy defect suggesting
that 
 
APG9
 
 is YDL149w.
 
Cell Viability Under Nitrogen Starvation Conditions
 
To examine the survival of various yeast strains under nitrogen starvation
conditions, cells were grown to an OD
 
600
 
 
 
5 
 
1 in SMD, washed in SD(2N),
and then resuspended in SD(2N) to an OD600 5 1. At the indicated times,
aliquots were removed and plated onto YPD plates in triplicate. Colonies
that survived the nitrogen starvation regimen were counted after 2–3 d.
Construction of Plasmids
For epitope-tagging Apg9p, a BamHI site was generated next to the initia-
tion methionine of APG9 in plasmid pRS424 or pRS426. A DNA frag-
ment encoding a 33HA epitope with BamHI sites on both sides was then
ligated into the BamHI site.
To construct the APG9GFP centromeric and multicopy plasmids, the
APG9 gene, including 509 bp of upstream sequence, was PCR-amplified
from the pAPG9(414) template using oligonucleotides that incorporated a
NotI site in the 59 primer (59-GCAAGGTTGGGTCTATGCGGCCG-
CACAAATCTGG-39) and an in-frame BamHI site immediately preced-
ing the APG9 stop codon in the 39 primer (59-GACACAGTCTGCCT-
TAGGATCCGAC-39). The 3.5-kb PCR product was subcloned into
pCGFP(416) and pCGFP(426), which contained the green fluorescent
protein (GFP) ORF, followed by actin termination sequences (Kim
et al., 1999). The resulting COOH-terminal GFP fusion constructs,
pAPG9GFP(416) and pAPG9GFP(426), were tested for their ability to
rescue the prAPI import defect in the apg9D strain.
Cell Labeling
For cell labeling experiments, cells were grown to OD600 5 1 and resus-
pended in SMD at 20–30 OD600/ml. The resuspended cells were labeled
with 10–20 mCi of 35S Express label/OD600 for the indicated times, fol-
lowed by a chase reaction in SMD supplemented with 0.2% yeast extract,
4 mM methionine, and 2 mM cysteine at a final cell density of 1 OD600/ml.
The labeled cells were precipitated with 10% TCA on ice, followed by two
acetone washes. Crude extracts were prepared by glass bead lysis, as de-
scribed previously (Harding et al., 1995).
Subcellular Fractionation
Wild-type cells were grown to midlog and incubated in 0.1 M Tris-HCl,
pH 7.5, containing 40 mM 2-mercaptoethanol for 10 min at room tempera-
ture. Following a centrifugation step, the cells were spheroplasted in 1.2 M
sorbitol, 50 mM Tris-HCl, pH 7.5, with 5 U/ml Zymolyase 100T at 308C
for 30–50 min. The cells were loaded on top of an equal volume of 1.8 M
sorbitol and centrifuged at 2,000 rpm for 10 min. The spheroplasts were
collected from the bottom of the tube. For sucrose density gradient frac-
tionation, YW5-1B cells were grown to midlog in YPD and spheroplasted
as described above. The spheroplasts were lysed in lysis buffer B (20 mM
triethanolamine, pH 7.2, 12.5% sucrose [wt/vol], 1 mM EDTA, 1 mM
PMSF, and protease inhibitor cocktail) at a density of 60 OD600/ml. After
removal of cell debris, the supernatant fraction (1 ml) was layered on top
of a sucrose density gradient consisting of 1-ml steps of 54, 50, 46, 42, 38,
34, 30, 26, 22, and 18% sucrose (wt/wt) in 10 mM Hepes-NaOH, pH 7.5,
1 mM MgCl2, and 1 mM PMSF. The gradients were subjected to centrifu-
gation in a Hitachi RPS40T rotor at 174,000 g for 2.5 h. Samples were col-
lected into 16 fractions from the top of the gradients. To examine Apg9p
in the ypt7D strain, the precleared lysate was subjected to centrifugation at
100,000 g for 1 h. The pellet was resuspended in lysis buffer B and centri-
fuged a second time at 100,000 g for 1 h. The pellet fraction after the sec-
ond centrifugation step was resuspended in 1 ml of lysis buffer B and sub-
jected to the same density gradient centrifugation as above for 16 h.
Endoglycosidase H Treatment
Strain CTD1 cells expressing 33HA Apg9p were grown to midlog phase
and converted to spheroplasts. The spheroplasts were lysed in 0.1% SDS,
50 mM sodium citrate, pH 5.5, 1 mM EDTA, 1 mM PMSF, protease inhib-
itor cocktail, and boiled for 5 min. After centrifugation at 14,000 rpm for
1 min, the protein concentration of the supernatant fraction was deter-
mined. Protein (60 mg) was diluted to 25 ml, and 25 ml 0.1% SDS, 0.1 M
2-mercaptoethanol were added, and the solution was boiled for 3 min. 15
ml of 0.5 M sodium citrate, pH 5.5, 75 ml H2O, 5 ml 100 mM PMSF, 2.5 ml
endo H (1 U/ml) were then added and the mixtures were incubated over-
night at 378C, boiled for 3 min, and subjected to immunoblotting.
Generation of the apg9ts Mutant
A strategy of gap-repair PCR mutagenesis (Muhlrad et al., 1992) was em-
ployed to generate a temperature conditional mutant of Apg9p. In brief, a
“gapped” APG9 plasmid was created by digestion with SpeI/BglII, which
removed a 1.74-kb piece of the APG9 ORF starting 228 bp downstream
of the ATG start site. A 2.23-kb PCR product of the APG9 ORF was
generated by using the primers 59-CACGGAATTATTAGGTTATG-
GAGAGAGATG-39 and 59-GTGTTATCATCAGGCTAGTGAGTT-
CCC-39 and pAPG9(414) as the template. Errors were introduced in the
polymerization reactions by the addition of 0.1 mM MnCl2. The resulting
mutagenized PCR product shares overlapping sequences of 245 bp at the
59 side and 240 bp at the 39 side with the gapped APG9 plasmid. The PCR
product and the gapped plasmid were cotransformed into the apg9D strain
and grown on 2Trp plates. The transformants were subjected to Western
blotting analysis with anti-API antiserum after growth on 2Trp plates
overnight at 25 or 378C. Out of the 400 colonies examined, four colonies
exhibited a mature API phenotype at 258C, indicative of functional
Apg9p, and a prAPI phenotype at 378C, the defective Apg9p phenotype.
The four potential apg9ts colonies were analyzed by pulse/chase labeling
to assess the kinetics of prAPI delivery to the vacuole at permissive and
nonpermissive temperatures.Noda et al. Apg9p Is Needed to Form Autophagic/Cvt Vesicles 469
Membrane Flotation Analysis
The procedure for the membrane flotation experiments is a modification
of a previously described protocol (Scott and Klionsky, 1995; Babst et al.,
1997; Kim et al., 1999). Spheroplasts from the apg9ts and the ypt7D
strains were pulse-labeled with Expre35S35S label for 10 min, followed by a
30-min chase at 388C. After centrifugation at 1500 g for 5 min, the sphero-
plasts were lysed in osmotic lysis buffer C (20 mM Pipes, pH 6.8, 200 mM
sorbitol, 5 mM MgCl2, Complete EDTA-free protease inhibitor cocktail)
at a spheroplast density of 20 OD600/ml. The lysate from 16 OD600 cell
equivalents was subjected to a 5,000 g centrifugation for 5 min, resulting in
low-speed supernatant (S5) and pellet (P5) fractions. The P5 fractions,
which contained all of the prAPI, were resuspended in 100 ml of 15% Fi-
coll-400 (wt/vol) in gradient buffer (GB; 20 mM Pipes, 5 mM MgCl2, Com-
plete EDTA-free protease inhibitor cocktail) with or without the addition
of 0.2% Triton X-100. The resuspended P5 fractions were overlaid with 1 ml
of 13% Ficoll-400 in GB and then 300 ml of 2% Ficoll-400 in GB. The re-
sulting step gradients were subjected to centrifugation at 15,000 g for 10
min at 258C in a microcentrifuge. Fractions were collected from the top.
The first 500 ml was the float fraction, the remaining 900 ml was the non-
float fraction, and the gradient pellet was considered the pellet fraction.
The resulting fractions were TCA precipitated and washed twice with ace-
tone before being immunoprecipitated with anti-API antiserum.
Protease Sensitivity Analysis
To examine the protease sensitivity of prAPI in the apg9ts and ypt7D
strains, spheroplasts were labeled for 10 min at 388C followed by a 30-min
chase reaction at 388C. Spheroplasts were lysed in osmotic lysis buffer C at
a spheroplast density of 20 OD600/ml. The resulting lysate (20 OD600 cell
equivalents per incubation condition) was separated into S5 supernatant
and P5 pellet fractions by centrifugation at 5,000 g for 5 min at 48C. The P5
pellet was resuspended in osmotic lysis buffer C in the presence or ab-
sence of proteinase K (50 mg/ml) and 0.2% Triton X-100. The resus-
pended P5 pellets were incubated on ice for 20 min, followed by TCA
precipitation, acetone wash, and immunoprecipitation with anti-API and
anti-PGK antisera.
Immunofluorescent Labeling, Immunoelectron 
Microscopy, and Confocal Microscopy
For immunofluorescent labeling of vegetatively growing cells, cultures
were grown to midlog in YPD. To examine cells under starvation condi-
tions, cells were grown in YPD and subsequently incubated in SD(2N)
with 1 mM PMSF for 3 h. The cells were fixed in 100 mM potassium phos-
phate, pH 6.5, containing 5% formaldehyde for 2 h at 238C. Following a
washing step in SHA buffer (1 M sorbitol, 0.1 M Hepes-NaOH, pH 7.5,
5 mM NaN3), the fixed cells were converted to spheroplasts by incubation
with 0.5 U/ml Zymolyase 100T, 24 mM 2-mercaptoethanol for 15 min at
308C. The spheroplasts were washed in SHA buffer and mounted on
polylysine-coated multiwell glass slides. The cells were permeabilized by
treatment with 0.1% Triton X-100 in PBS for 10 min. Permeabilized cells
were incubated with anti-HA mAb at a 1:5,000 dilution, and the FITC-
conjugated secondary anti-mouse antibody was used at a 1:50 dilution.
Photographs were taken using the confocal microscope Zeiss LSM510.
For EM, cells were subjected to rapid freezing and freeze-substitution
fixation, and observed as described previously (Baba et al., 1997). For im-
munoelectron microscopy, ultrathin sections were collected onto formvar-
coated nickel grids and blocked in PBS containing 2% BSA at room tem-
perature for 15 min. Incubations were carried out by floating grids on a
20 ml drop of a 1:1,500 dilution of anti-HA mAb, 16B12, at room tempera-
ture for 1.5 h. After washing, the grids were incubated for 1 h with 5-nm
gold-conjugated goat anti–mouse IgG. The grids were washed several
times in PBS followed by several drops of distilled water and fixed with
1% glutaraldehyde for 3 min. The sections were stained with 4% uranium
acetate for 7 min and examined.
Strains expressing the Apg9pGFP fusion protein were grown to midlog
and the vacuoles were labeled with FM 4-64 dye to a final concentration of
4–8 mM and incubated at 308C for 20 min to allow cells to take up the dye.
After a wash step, the cultures were resuspended in SMD for 2 h to allow
the dye to label the vacuole via endocytosis. Cells were examined on a
Leica DM IRB confocal microscope. The images captured were the result
of an average of eight scans of a single focal plane.
Software Programs
Hydrophobicity analysis was performed using the program TopPred II de-
veloped by M.-G. Claros (Laboratoire de Génétique Moléculaire, Paris,
France).
Immunoblots were scanned using a Power Macintosh G3 and GT-9000
scanner (EPSON), and band intensities were determined using the pro-
gram NIH Image 1.61.1. Alternatively, autoradiograms were quantified
using the Molecular Dynamics Storm PhosphorImager and Image-
Quant  5.0.
Results
Apg9p/Cvt7p Is a Shared Component of the 
Macroautophagy and Cvt Pathways
Autophagy is a degradative pathway used for delivery
of cytoplasm to the vacuole (reviewed in Klionsky and
Ohsumi, 1999; Kim et al., 2000). The Cvt pathway is a bio-
synthetic process that targets at least one resident hydro-
lase to the vacuole (Klionsky et al., 1992). There are clear
differences in the conditions that induce either pathway
and in their kinetic parameters (Klionsky and Ohsumi,
1999). Nonetheless, genetic analyses reveal a substantial
overlap between the machinery employed by each process
for the delivery of their corresponding cargo to the vacu-
ole (Harding et al., 1996; Scott et al., 1996). The apg9 and
cvt7 mutants were isolated by screening for starvation sen-
sitivity or accumulation of prAPI, respectively (Tsukada
and Ohsumi, 1993; Harding et al., 1995). We also isolated
apg9 by a third strategy in this study, by screening for mu-
tants that were unable to deliver a recombinant cytosolic
marker protein (Pho8D60p) to the vacuole under induced
autophagy conditions (see Materials and Methods; Fig. 1).
Genetic analyses suggest that apg9 and cvt7 are in the
same complementation group. Consistent with these mu-
tations being allelic, both mutants accumulate prAPI and
exhibit autophagy defects including sensitivity to nitrogen
starvation. The nitrogen sensitivity phenotype was used as
a basis for cloning the complementing genes. apg9-1 and
cvt7-1 were transformed with a plasmid-based yeast ge-
nomic library. The plasmids from cells that survived the
prolonged nitrogen starvation regimen were isolated. Af-
ter further manipulations, our two laboratories indepen-
dently identified YDL149w as the ORF whose gene prod-
uct rescued the nitrogen sensitivity of both the apg9-1 and
cvt7-1 mutants. We will refer to this ORF as APG9 hereaf-
ter in this study. Both the single copy and multicopy plas-
mids of APG9 rescued the prAPI processing defect in the
apg9 mutants, as well as in the apg9D null mutant (Fig. 2
A), although overexpression of APG9 caused a slight ac-
cumulation of prAPI. Furthermore, the nitrogen starva-
tion sensitivity was also rescued by the APG9 plasmid,
showing survival rates similar to the isogenic wild-type
strain (Fig. 2 B). These findings confirm that Apg9p is a
required component for both the Cvt pathway and au-
tophagy.
Apg9p/Cvt7p Is an Integral Membrane Protein
A search of the databases indicates that Apg9p does not
share significant homology with other characterized pro-
teins. Apg9p encodes a protein of 998 amino acids and has
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terize the protein, antisera were generated to two sets of
synthetic Apg9p peptides. Both Apg9p antisera recog-
nized a band with a molecular mass of z125 kD by West-
ern blotting analysis. The expression level of the protein
was low in immunoblots prepared from wild-type yeast
cell lysates and increased in a dose-dependent manner in
apg9D cells transformed with the single copy or multicopy
APG9 plasmid (Fig. 3 A). No signal was detected in the
predicted mass range of Apg9p in the null mutant. These
results indicate that the antisera specifically recognized
the Apg9p protein. The expression level of Apg9p ap-
peared constant under both vegetative growth and starva-
tion conditions as examined by pulse/chase labeling and
steady-state analyses (data not shown). In addition, no ele-
vation in transcription was detected with microarray anal-
ysis during sporulation or stationary phase, conditions that
are equivalent to starvation (DeRisi et al., 1997; Chu et al.,
1998).
Hydrophobicity analysis of the Apg9p sequence predicts
six to eight membrane-spanning regions with significant
hydrophilic domains of z35 and z25 kD at the NH2 and
COOH termini, respectively (Fig. 3 B). To assess whether
Apg9p is an integral membrane protein, a detergent ex-
traction procedure was performed. Wild-type cells were
converted to spheroplasts, osmotically lysed in conditions
that disrupt the plasma membrane but preserve vacuole
membrane integrity, and incubated in a lysis buffer with or
without 2% Triton X-100. After a 10,000 g centrifugation
step, Apg9p appeared predominantly in the pellet fraction
in the absence of detergent (Fig. 3 C). The detergent ex-
traction procedure solubilized Apg9p, resulting in its ap-
pearance in the supernatant fraction. These results, cou-
pled with the hydrophobicity analysis, suggest that Apg9p
is an integral membrane protein.
Most integral membrane proteins enter the ER translo-
con complex before being directed via part of the secre-
tory machinery to their final intracellular destinations.
During transit through the secretory pathway, many inte-
gral membrane proteins undergo posttranslational modifi-
cation in the ER and Golgi complex including the addition
of glycosyl residues. Although the molecular mass of
Apg9p did not appear to change over the course of a
pulse/chase labeling experiment (data not shown), we
wanted to determine if Apg9 was glycosylated. Cell lysates
were treated with endo H to cleave potential N-linked oli-
gosaccharides from Apg9p. As a control, the glycosylated
protein CPY was also examined. There was a significant
shift in size between untreated and endo H-treated sam-
ples of CPY (Fig. 3 D). In contrast, Apg9p did not demon-
strate a change in electrophoretic mobility upon endo H
treatment, suggesting that Apg9p does not contain any
N-linked glycosyl modifications.
Figure 2. Cloning and char-
acterization of APG9. A,
Wild-type (WT; SEY6210),
apg9  (THY154),  apg9D
(JKY007), and the apg9D
strain transformed with
single  copy (CEN;
pAPG9(414)) or multicopy
(2m; pAPG9(424)) plasmids
encoding APG9 were grown
to log phase in SMD. Protein
extracts were prepared and
analyzed by immunoblot us-
ing antiserum to API as de-
scribed in Materials and Methods. The positions of precursor and
mature API are indicated. The APG9 gene complements the
prAPI accumulation phenotype of the apg9D  mutant. B, WT
(SEY6210), apg9D (JKY007), and the apg9D strain transformed
with pAPG9(414) centromeric plasmid were grown in SMD and
transferred to SD(2N) as described in Materials and Methods.
Aliquots were removed at the indicated times and spread onto
YPD plates in triplicate. Numbers of viable colonies were deter-
mined after two to three days. The APG9 gene complements the
starvation-sensitive phenotype of the apg9D mutant.
Figure 3. Apg9p is an unglycosylated, integral membrane pro-
tein. A, Wild-type (WT; SEY6210), apg9D (JKY007), and the
apg9D strain transformed with single copy (CEN) or multicopy
(2m) plasmids encoding APG9 were grown to log phase in SMD.
Protein extracts were prepared and analyzed by immunoblot us-
ing antiserum to Apg9p. Apg9p is detected as an z125-kD pro-
tein. B, Hydrophobicity analysis of Apg9p based on the Kyte-
Doolittle algorithm (Kyte and Doolittle, 1982) predicts six to
eight transmembrane domains. C, Cells of wild-type strain YW5-
1B were grown in YPD, converted to spheroplasts, and osmoti-
cally lysed as described in Materials and Methods. After a pre-
clearing step to remove cell debris, the lysates were incubated
with or without 1% Triton X-100 on ice for 30 min, as indicated.
Centrifugation at 10,000 g for 1 h separated the lysate into super-
natant (S) and pellet (P) fractions, which were analyzed by im-
munoblots with antiserum to Apg9p. Apg9p is found in the low-
speed pellet in the absence of Triton X-100. Detergent extraction
completely solubilizes Apg9p and causes it to appear in the su-
pernatant fraction. D, Strain CTD1 harboring a multicopy
33HA  APG9 plasmid was grown in YPD and converted to
spheroplasts as described in Materials and Methods. A crude ly-
sate was prepared and treated with or without endo H as indi-
cated overnight at 378C and analyzed by immunoblots with anti-
HA antibodies or anti-CPY serum. Endo H treatment removes
the N-linked glycosyl residues of CPY, causing a shift in its elec-
trophoretic mobility. In contrast, Apg9p is not glycosylated and
remains unchanged in the presence or absence of endo H treat-
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Subcellular Fractionation and Sucrose Density Analysis 
of Apg9p
The pelletability and detergent extraction of Apg9p sug-
gested that it is localized to a membrane compartment.
Membrane association was also supported by differential
centrifugation procedures in which Apg9p appeared in
both low- and high-speed pellet fractions (data not shown).
The distribution of Apg9p to either the low- or high-speed
pellet was partially dependent on lysis buffer conditions
(data not shown). To further examine the identity of the
Apg9p membrane compartment, cell lysates were ana-
lyzed by sucrose density gradients (Fig. 4). Spheroplasts
from wild-type cells were osmotically lysed and, after re-
moval of cell debris, the precleared lysates were subjected
to density gradient centrifugation. The gradient was com-
prised of ten sucrose steps ranging from 18–54% (wt/wt).
After centrifugation at 174,000 g for 2.5 h, 16 fractions
were collected from the top and examined by immunoblot
analysis (Fig. 4). The peak concentration of Apg9p ap-
peared in the light fractions three to five, while vacuoles
fractionate to the top of the gradients as indicated by the
vacuole membrane marker alkaline phosphatase (Pho8p;
Fig. 4 A). Apg9p was not detected by immunoblot analysis
of a purified vacuole preparation (data not shown), con-
firming the sucrose gradient findings. Thus, Apg9p does
not appear to be a vacuolar membrane protein. Marker
proteins for other organelles including ER (Sec12p), Golgi
complex (Kex2p), and the plasma membrane (Pma1p) all
failed to comigrate with the peak for Apg9p (Fig. 4). The
endosomal marker Pep12p showed a partial cofraction-
ation with Apg9p, but displayed a broad distribution
across the gradient (Fig. 4 B). These findings suggest that
Apg9p is localized to a membrane compartment distinct
from known organelles of the endomembrane system, al-
though we cannot exclude an overlap with the endosome.
The finding that Apg9p did not colocalize with known
endomembrane markers suggested that it may be on the
autophagosomal membrane, for which there are no known
integral membrane markers. To circumvent this problem,
we examined the localization of Apg9p in relation to
prAPI in a strain with a chromosomal deletion of the rab
GTPase Ypt7p on sucrose density gradients. A null muta-
tion in YPT7 prevents Cvt and autophagic vesicles from
fusing with the vacuole, resulting in the accumulation of
prAPI inside Cvt vesicles and autophagosomes in the cyto-
sol (Kim et al., 1999; Kirisako et al., 1999). Therefore, den-
sity gradients should resolve Apg9p and prAPI to the
same peak fractions if they are colocalized on or within
Cvt/autophagic vesicles in the ypt7D strain. Spheroplasts
from ypt7D cells grown to midlog stage were osmotically
lysed and, after removal of cell debris, the precleared ly-
sates were subjected to centrifugation at 100,000 g to
remove soluble prAPI. The resulting pellet fraction was
subjected to equilibrium density gradient centrifugation.
After a 16-h centrifugation, 16 fractions were collected
and examined with antisera to API and Apg9p (Fig. 5).
The peak for prAPI appeared in fraction 7, whereas the
peak for Apg9p migrated to fractions 8 and 9. These re-
sults suggest that Apg9p does not colocalize with the trans-
port vesicles that deliver prAPI to the vacuole.
Apg9p Localizes to Punctate Structures that Appear 
Proximal to the Vacuole
The sucrose gradient analysis indicated that the Apg9p
fractionation pattern did not correspond to any endomem-
brane marker proteins or with Cvt vesicles. Therefore, we
wanted to understand its subcellular localization from a
morphological perspective. Along these lines, we first ex-
amined Apg9p by immunofluorescence microscopy. The
apg9D strain was transformed with a multicopy plasmid
encoding HA-tagged Apg9p. The 33HA APG9 plasmid
rescues the prAPI processing defect in the apg9D strain,
indicating that the fusion protein is functional (data not
shown). The apg9D strain harboring the 33HA  APG9
plasmid was fixed and labeled with an anti-HA mAb, fol-
lowed by a FITC-conjugated anti-mouse secondary anti-
body as described in Materials and Methods. Under vege-
tative growth conditions, one or two prominent punctate
structures were detected per cell. In addition, these punc-
tate structures appeared to be adjacent to the vacuole in
Figure 4. Apg9p does not
comigrate with typical en-
domembrane markers in su-
crose density gradients. A
and B, Strain STY1 (pep4D)
was grown in YPD to log-
phase, and osmotically lysed.
Lysates were precleared,
loaded on a sucrose density
gradient ranging from 18–
55% (wt/wt), and centri-
fuged for 2.5 h at 174,000 g as
described in Materials and
Methods. Fractions were col-
lected from the top (fraction
number 1) to the bottom
(fraction number 16). Frac-
tions were subjected to SDS-
PAGE and immunoblot with
antiserum against Apg9p and: in A, Kex2p (trans Golgi net-
work), Pho8p (vacuole), and Pma1p (plasma membrane); and in
B, Sec12p (ER) and Pep12p (endosome). The graphs in panels A
and B are from the same gradient, but are presented separately
for clarity.
Figure 5. Apg9p does not
comigrate with prAPI in a
strain that accumulates Cvt/
autophagic vesicles. Strain
TK415 (ypt7D) was grown in
YPD to log-phase, and os-
motically lysed. Lysates were
precleared, centrifuged at
100,000  g for 1 h, and the pel-
let fraction resuspended and
centrifuged a second time.
The resulting pellet fraction was subsequently loaded on a su-
crose density gradient ranging from 18–55% (wt/wt), and centri-
fuged for 16 h at 174,000 g as described in Materials and Meth-
ods. 16 fractions were collected starting from the top and
subjected to SDS-PAGE and immunoblot with antisera against
Apg9p and API. The graph represents an average of two experi-
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most cases (Fig. 6). When cells were subjected to star-
vation conditions in the presence of PMSF, autophagic
bodies accumulated inside of the vacuole. However, the
Apg9p punctate structures persisted outside of the vacu-
ole, suggesting that Apg9p is not a constituent of the au-
tophagic body vesicle and does not enter the vacuole (Fig. 6).
The sucrose gradient data indicated that Apg9p shows
partial cofractionation with the endosomal/prevacuolar
compartment marker Pep12p. To further study this over-
lap, we examined the localization of Apg9p in the vps4D
strain. The vps4D strain is a member of the class E vps mu-
tants exhibiting the phenotype of accumulated endosomal
structures (Babst et al., 1997, 1998; Finken-Eigen et al.,
1997; Shirahama et al., 1997). We reasoned that if Apg9p
is localized to an endosomal structure, then the accumula-
tion of this compartment in vps4D would also result in a
corresponding enlargement of the Apg9p punctate struc-
tures. However, no increase in the size of Apg9p-labeled
punctate structures was detected (Fig. 6). In addition, we
examined the localization of Apg9p in the apg6D mutant.
The APG6 gene was identified as being essential for au-
tophagy and was shown to be identical to VPS30 (Kame-
taka et al., 1998). Vps30p is required for recycling of the
CPY receptor Vps10p from the endosome to the Golgi
complex. The vps30 mutation results in mislocalization of
the integral membrane Vps10p to the vacuole. However,
there was no significant change in the immunofluores-
cence pattern of Apg9p in this mutant strain (Fig. 6).
Taken together, these results indicate that Apg9p is local-
ized to large punctate structures that appear to be near the
vacuole, but do not overlap with the vps4D- or apg6D-
enhanced prevacuolar compartment.
The in situ data obtained from indirect labeling of
Apg9p by immunofluorescence microscopy indicated that
Apg9p was primarily restricted to patches near the vacu-
olar membrane. We decided to extend our analysis of lo-
calization by examining Apg9p in vivo. To investigate the
subcellular location of Apg9p in vivo, we constructed a fu-
Figure 6. Apg9p localizes to
large perivacuolar punctate
structures. Immunofluores-
cence microscopy of strains
CTD1 (apg9D), KSL12C
(vps4D), and SKD6-1D
(apg6D) transformed with the
multicopy plasmid 33HA
APG9. Cells were grown in
YPD to log phase (vegeta-
tive), and incubated further
in SD(2N) medium with 1
mM PMSF for 3 h (starva-
tion). The cells were fixed
with formaldehyde and ex-
amined by immunofluores-
cence microscopy as de-
scribed in Materials and
Methods. Anti-HA and
FITC-conjugated antibodies
mark Apg9p (left), and the
vacuole can be visualized by
Nomarski optics (middle).
An overlay is shown in the
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sion of GFP to the COOH terminus of Apg9p, and exam-
ined the localization by confocal fluorescence microscopy.
Both the single copy and multicopy plasmids expressing
Apg9pGFP complement the API processing defect in the
apg9D strain, suggesting that the fusion protein is func-
tional (data not shown). As with immunofluorescence
microscopy, Apg9pGFP could only be detected reliably
when expressed with the multicopy plasmid, pAPG9-
GFP(426).
Wild-type and apg9D cells transformed with pAPG9-
GFP(426) were grown to midlog and examined by both
conventional and confocal microscopy. To evaluate the lo-
cation of the Apg9pGFP structures relative to the vacu-
oles, FM 4-64, a lipophilic styryl dye, was used to label this
Figure 7. In vivo examina-
tion of the Apg9pGFP fusion
protein. Wild-type (SEY6210)
cells expressing Apg9pGFP
from a multicopy plasmid
were grown in SMD to mid-
log phase and labeled with
FM 4-64 to stain the vacuoles
as described in Materials and
Methods. The labeled cells
were viewed directly with a
Leica DM IRB confocal mi-
croscope. Large, punctate
Apg9pGFP structures ap-
pear juxtaposed to the FM
4-64–labeled vacuole mem-
branes. In addition, smaller
punctate structures appear
throughout the cytoplasm.The Journal of Cell Biology, Volume 148, 2000 474
organelle (Vida and Emr, 1995). In nearly all cases, one
to several prominent Apg9pGFP punctate structures
were  detected juxtaposed to the FM 4-64–labeled vacuoles
(Fig. 7). However, in addition to these perivacuolar struc-
tures, smaller punctate structures could also be detected
throughout the cytosol. These observations suggest that
Apg9p may not be exclusively localized in large structures
near the vacuole, but may also be distributed in smaller
membrane compartments/vesicles throughout the cyto-
plasm (Fig. 7). Consistent with the biochemical and immu-
nomicroscopy data, Apg9pGFP appears to be excluded
from the vacuolar lumen.
To obtain ultrastructural information about the identity
of the Apg9p structures, we examined the localization of
Apg9p by immunoelectron microscopy. Thin sections of
the apg9D strain harboring the 33HA  APG9  plasmid
were labeled with an anti-HA mAb, followed by gold par-
ticle-conjugated anti-mouse secondary antibody and ex-
amined by EM. In agreement with the immunofluores-
cence and Apg9pGFP results, the immunogold particles
were strongly concentrated to one or two structures adja-
cent to the vacuolar membrane (Fig. 8). Weaker immu-
nogold labeling also appeared dispersed throughout the
cell. Significantly, the immunogold labeling did not appear
to encircle any vesicular structures and was not found to
coincide with the autophagic bodies that accumulated in
the vacuole lumen in a pep4D strain (Fig. 8 A) or on au-
tophagosomes in the cytoplasm (Fig. 8 B), supporting the
Apg9p density gradient analysis (Fig. 5). Taken together,
these biochemical and morphological findings suggest that
Apg9p may reside in a perivacuolar location that is largely
distinct from known endomembrane compartments.
Apg9p Functions Early in the Autophagy and
Cvt Pathways
We have determined that Apg9p is an integral membrane
protein required for both the Cvt and autophagy path-
ways. It is localized to a dense membrane fraction that does
not appear to comigrate with known organellar marker
proteins. The subcellular localization of Apg9p appears
to be in large punctate structures adjacent to the vacuole,
but also within smaller punctate structures distributed
throughout the cytosol. We next wanted to investigate the
direct function of Apg9p in the Cvt and autophagy path-
ways. The first indication of the step at which Apg9p may
function came from a vesicle test of the apg9D strain (Fig.
9 A). Under vegetative growth conditions when autophagy
is not induced, both apg9D and wild-type cells appear de-
void of autophagic bodies in the vacuole. However, when
these cells are starved in the presence of PMSF, which pre-
vents the breakdown of autophagic bodies, only wild-type
cells or mutant strains defective in subvacuolar vesicle
breakdown accumulate these intravacuolar vesicles. The
lack of autophagic bodies in the apg9D strain is rescued by
the plasmid-borne copy of APG9 (data not shown). This
observation suggests that Apg9p acts early in the autoph-
agy pathway, before the fusion of the autophagosomes
with the vacuole and the release of the autophagic bodies
into the vacuolar lumen.
The permanent loss of function in the apg9D null mutant
may result in phenotypes that are indirect. To determine
the direct effects of Apg9p loss of function, we generated
a temperature conditional mutant of Apg9p by a PCR
procedure that randomly incorporated mutations in the
APG9 ORF (see Materials and Methods). The tempera-
ture-sensitive apg9 mutant (apg9ts) was originally isolated
based on an immunoblot procedure selecting for mutants
that accumulated prAPI at nonpermissive temperature. A
kinetic analysis of apg9ts was subsequently performed by
radioactive pulse labeling, followed by nonradioactive
chase reactions at the indicated times (Fig. 9 B). The
apg9ts mutant displayed near wild-type prAPI maturation
kinetics at permissive temperature. However, at nonper-
missive temperature, prAPI import was tightly blocked in
Figure 8. Ultrastructural localization of Apg9p for immunoelec-
tron microscopy. Strain STY1 (pep4D) expressing 33HA Apg9p
was grown in YPD to log phase and transferred to SD(2N) me-
dium for 2 h. The cells were fixed and stained with anti-HA anti-
body and 5-nm colloidal gold-conjugated goat anti–mouse IgG as
described in Materials and Methods. A, Section showing auto-
phagic bodies in the vacuole lumen. B, Section showing a cytoso-
lic autophagosome. Apg9p is seen in patches near the vacuole,
but not on autophagic bodies or autophagosomes. AB, auto-
phagic body; AP, autophagosome; N, nucleus; V, vacuole; VM,
vacuolar membrane. Arrows point to areas of concentrated
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the apg9ts strain (Fig. 9 B). The immediate block in prAPI
processing suggested that Apg9p acts directly within the
Cvt pathway.
Apg9p Is Required for the Vesicle Formation Step
To determine the step of the Cvt pathway/autophagy in
which Apg9p functions, we analyzed the state of prAPI in
the apg9ts mutant after shift to nonpermissive tempera-
ture. In the first steps of import, prAPI oligomerizes into a
dodecamer and then assembles into a higher order pellet-
able Cvt complex (Baba et al., 1997; Kim et al., 1997; Fig.
1). In wild-type cells, pelletability of the Cvt complex is
salt dependent. Accordingly, we first examined the nature
of prAPI binding and pelleting. In wild-type cells, prAPI is
pelletable at 5,000 g when cell lysates are prepared in the
presence of physiological salt concentrations. In contrast,
prAPI is located in a soluble fraction in the absence of salt.
To examine salt dependent pelletability of prAPI in the
apg9ts strain, spheroplasts of apg9ts were pulse-labeled for
10 min, followed by a chase reaction of 30 min, all at non-
permissive temperature. The labeled spheroplasts were os-
motically lysed in a buffer containing no salt or a physio-
logical concentration of salt, and separated into low-speed
supernatant and pellet fractions (Fig. 10 A). In lysis condi-
tions containing no salt, the majority of prAPI is soluble,
whereas it appears in the pellet fraction in the apg9ts strain
when salt is introduced into the osmotic lysis conditions.
This result indicates that apg9ts retains the salt dependent
binding and pelleting of prAPI. In addition, the pelletable
nature of prAPI suggests that prAPI is able to form the
Cvt complex in the apg9ts strain.
Biochemical and EM findings indicate that the Cvt com-
plex associates with a membrane source that eventually
forms the double-membrane vesicle. To determine if the
Cvt complex in the apg9ts strain contained membrane con-
stituents, we performed membrane flotation gradients. In
this analysis, membrane-associated proteins would “float”
up the gradient (F), whereas soluble proteins would re-
main in the nonfloat (NF) fraction, and proteins associated
with large protein complexes would be recovered as a gra-
dient pellet (P2). In addition to the apg9ts strain, we also
examined prAPI in the ypt7D strain by flotation gradients.
Spheroplasts of apg9ts and ypt7D were pulse-labeled for
10 min, followed by a 30-min chase reaction, all at nonper-
missive temperature. The labeled spheroplasts were os-
motically lysed and separated into 5,000 g supernatant (S)
and pellet (P) fractions. The prAPI-containing pellet frac-
tions were then subjected to flotation gradients (see Mate-
rials and Methods). In the apg9ts strain, the majority of
Figure 9. Vesicle accumulation test and kinetic analysis of prAPI
import in the temperature conditional Apg9p mutant. A, Mor-
phological analysis of apg9D indicates an import defect at an
early step in the pathway. Wild-type (YW5-1B) and apg9D
(CTD1) cells were grown in YPD (vegetative) or transferred to
SD(2N) (starvation) for 3 h in the presence of PMSF (starva-
tion) and examined by DIC (Nomarski) microscopy (Zeiss Ax-
ioplan). PMSF inhibits the degradation of autophagic bodies.
Under starvation conditions, wild-type cells accumulate auto-
phagic bodies when vesicle breakdown is blocked. However, un-
der the same conditions, apg9D cells do not accumulate auto-
phagic bodies, indicating that Apg9p is required for a step before
vesicle fusion and release of the autophagic body into the vacu-
olar lumen. The apg9D strain transformed with the APG9 plas-
mid shows the same result as wild-type (data not shown). B, The
apg9ts strain is tightly blocked for prAPI import at nonpermis-
sive temperature. Wild-type (SEY6210) and apg9D (JKY007)
cells transformed with the apg9ts centromeric plasmid were incu-
bated at 24 and 388C for 5 min, pulse-labeled for 10 min, and then
subjected to nonradioactive chase reactions for the indicated
times. Samples at each time point were immunoprecipitated with
antiserum to API and resolved by SDS-PAGE as described in
Materials and Methods. API-immunoprecipitated bands were
quantified by a Molecular Dynamics STORM PhosphorImager
and the results are presented in the graph. The percent mature
API was determined by dividing the mature API value over the
sum of the precursor and mature API values for each time point.The Journal of Cell Biology, Volume 148, 2000 476
prAPI was found in the float fraction with a significant
amount also appearing in the P2 pellet fraction (Fig. 10 B).
In the presence of detergent, prAPI appeared entirely in
either the nonfloat (NF) or the pellet (P2) fraction. These
results suggested prAPI in the apg9ts strain associated
with a large pelletable complex possessing a membrane
component that causes the complex to float. Detergent
treatment solubilizes this membrane component and dis-
rupts the flotation of the prAPI-containing complex. In
addition, there was an increase in the amount of prAPI in
the nonfloat fraction, suggesting that detergent treatment
liberated a portion of prAPI from either the float fraction
or the P2 pellet fraction into the nonfloat fraction. The flo-
tation pattern of prAPI from the ypt7D strain appeared
nearly identical to apg9ts (Fig. 10 B). A significant portion
of prAPI was found in the float fraction, as well as in the
P2 pellet fraction. However, unlike apg9ts, detergent treat-
ment during flotation in the ypt7D strain caused prAPI to
be localized almost entirely to the P2 fraction. These re-
sults suggest that the prAPI-associated complex in the
float fractions may be structurally distinct in these two mu-
tant strains.
We recently reported that prAPI in the ypt7D strain is
protease-protected based on steady state immunoblot
analysis (Kim et al., 1999). In addition, a ypt7 mutant
strain accumulates autophagosomes in the cytosol, further
demonstrating that Ypt7p acts at the step of vesicle fusion
with the vacuole (Kirisako et al., 1999). Given that the flo-
tation pattern of newly synthesized prAPI in the apg9ts
strain is essentially identical to ypt7D, we wanted to de-
termine if the membrane-association in apg9ts reflected
enclosure in a completed vesicle. This would result in pro-
tection of prAPI from exogenously added proteases. Al-
ternatively, if Apg9p is required for the completion of ves-
icle formation, then prAPI would be sensitive to protease
treatment and processed to the mature form in the apg9ts
strain. Spheroplasts of apg9ts and ypt7D were pulse-labeled
for 10 min, followed by a 30-min chase reaction, all at non-
permissive temperature. After osmotic lysis and low-speed
centrifugation, the prAPI-containing pellet fraction was
subjected to proteinase K treatment in the presence or ab-
sence of detergent. In agreement with previous steady
state data (Kim et al., 1999), the pulse-labeled population
of prAPI in the ypt7D strain was protected from exoge-
nously added protease and was digested only after deter-
gent treatment (Fig. 10 C). In contrast, prAPI from apg9ts
was completely sensitive to proteolysis, independent of de-
tergent addition, suggesting that membrane had not com-
pletely enwrapped the Cvt complex in this strain. The
small amount of protease resistant prAPI in the apg9ts
strain probably reflects incomplete spheroplast lysis based
Figure 10. Analysis of the apg9ts strain indicates Apg9p is di-
rectly required for the vesicle formation step. A, The nature of
prAPI binding and pelleting in the apg9ts strain. Spheroplasts of
apg9ts were labeled for 10 min and chased for 30 min at 388C.
The spheroplasts were osmotically lysed in a buffer containing no
salt (20 mM Pipes, pH 6.8) or a physiological concentration of
salt (100 mM KOAc, 50 mM KCl, 5 mM MgCl2, 20 mM Pipes, pH
6.8) and pelleted at 5,000 g. All samples were immunoprecipi-
tated with antiserum to API and the cytosolic marker PGK.
apg9ts  retains the salt dependent binding and pelleting of prAPI.
B, prAPI in the apg9ts strain accumulates in both a membrane-
associated state and a large pelletable complex. Spheroplasts of
apg9ts and ypt7D were labeled for 10 min and chased for 30 min
at 388C. The labeled spheroplasts were then osmotically lysed
and separated into supernatant (S) and pellet (P) fractions by
centrifugation at 5,000 g for 5 min. An aliquot was removed for
the total lysate control (T). The pellet fraction (P) was resus-
pended in 15% Ficoll-400 in gradient buffer (20 mM Pipes, 5 mM
MgCl2, complete EDTA-free protease inhibitor cocktail) in the
presence or absence of Triton X-100 and overlaid with 13 and 2%
Ficoll-400 in gradient buffer. The step gradients were centrifuged
at 13,000 g for 10 min. Membrane-containing float (F), nonfloat
(NF), and pellet (P2) fractions were immunoprecipitated with an-
tiserum to API as described in Materials and Methods. The posi-
tion of prAPI is indicated. C, prAPI in the apg9ts strain is pro-
tease accessible. Spheroplasts isolated from apg9ts and ypt7D
cells were pulse-labeled for 10 min and chased for 30 min at 388C.
The labeled spheroplasts were then osmotically lysed and sepa-
rated into low-speed supernatant (S) and pellet (P) fractions af-
ter a 5,000 g centrifugation step. The pellet fractions were sub-
jected to protease treatment in the absence or presence of 0.2%
Triton X-100 as described in Materials and Methods. The result-
ing samples were immunoprecipitated with antiserum to API and
PGK. The immunoprecipitated bands were quantified by a Mo-
lecular Dynamics STORM PhosphorImager. The percent pro-
tease-protected prAPI was determined by dividing the value for
prAPI in the protease-treated sample by the value for total
prAPI before protease treatment. The percent PGK was deter-
mined by dividing the supernatant (S) or pellet (P) value over the
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upon localization of slightly elevated levels of the cytosolic
marker PGK in the pellet fraction. Taken together, these
results indicate that Apg9p plays a direct role in formation
of the sequestering vesicle.
Discussion
The Stages of API Import Can Be
Tested Experimentally 
The import of prAPI can be delineated into discrete stages
(Fig. 1; Kim et al., 1999). Many of these steps can be tested
using straightforward biochemical and morphological as-
says. Thus, the model for prAPI import offers a conve-
nient framework through which we can assign the role of a
particular component in the Cvt and autophagy pathways
based on the state of API in the respective mutant back-
ground. For example, in the first step of the pathway, the
ability of prAPI to properly oligomerize in a given cvt or
apg mutant can be detected by glycerol gradient analysis
and by native gel electrophoresis measurements (Kim et
al., 1997). While newly synthesized prAPI dodecamers are
soluble, the Cvt complex, which results from the salt de-
pendent binding and assembly of prAPI into a supermo-
lecular structure, is easily pelletable by low-speed centrifu-
gation (Kim et al., 1997). The next step of the pathway
involves the formation of the sequestering membrane
around the Cvt complex. Examining the flotation compe-
tence of prAPI through a step gradient can identify the
presence of an enwrapping membrane (Kim et al., 1999;
George et al., 2000). The subsequent completion of the se-
questering membrane to form the Cvt vesicle or the au-
tophagosome ensures the protection of prAPI from exoge-
nous protease treatment (Scott et al., 1997). The successful
fusion of the Cvt vesicles or the autophagosomes with the
vacuole can be examined by observing the lumenal accu-
mulation of the single-membrane Cvt or autophagic bod-
ies in the presence of inhibitors for inner vesicle break-
down (e.g., PMSF; Takeshige et al., 1992; Scott et al.,
1997). Finally, if the existence of these Cvt or autophagic
bodies persists, even in the absence of inhibitors, then the
defect can be assigned to the final step of vesicle break-
down (Scott et al., 1997). In addition, vesicles that accumu-
late at the pre- and postvacuole fusion stages can be bio-
chemically purified in their respective mutant background
(e.g., ypt7 and cvt17, respectively; Scott et al., 1997).
Apg9p Functions at the Step of Vesicle Formation
Using the methods outlined above, we sought to charac-
terize the role of Apg9p in the Cvt and autophagy path-
ways. prAPI oligomerization and Cvt complex assembly
were both normal in the apg9 mutant backgrounds (Kim
et al., 1997; Fig. 10 A), suggesting that the role of Apg9p is
downstream of these early import steps. Examination of
apg9D under starvation conditions indicated that, unlike
wild-type cells, apg9D does not accumulate autophagic
bodies in the vacuole, even when inhibitors that prevent
vesicle breakdown are added (Fig. 9 A). Therefore, the
role of Apg9p appears to be before vesicle fusion to the
vacuole and subsequent release of autophagic bodies into
the vacuolar lumen. This restricted the possible steps of
Apg9p function to the membrane sequestration event and
the formation of the double-membrane around the Cvt
complex.
To directly assess the role of Apg9p in the Cvt and au-
tophagy pathways, we have isolated the first temperature-
sensitive allele of an integral membrane protein involved
in both autophagy and Cvt pathways. By investigating the
state of prAPI in the apg9ts strain, we have determined the
direct consequence that is caused by an immediate loss of
Apg9p function on prAPI import. The apg9ts mutant dis-
played near wild-type prAPI import kinetics at permissive
temperature, but exhibited a strong block in prAPI matu-
ration at nonpermissive temperature (Fig. 9 B). Biochemi-
cal analysis of apg9ts at nonpermissive temperature indi-
cated that prAPI was localized to a low-speed pellet in a
salt dependent manner (Fig. 10 A), suggesting that the Cvt
complex was able to form. This prAPI-bound pellet associ-
ates with a membrane component that permits it to float
through a ficoll step gradient (Fig. 10 B). Finally, protease
protection analysis of prAPI at nonpermissive tempera-
ture demonstrates that the vesicles that form around the
Cvt complex are incomplete, allowing prAPI to be accessi-
ble to protease digestion (Fig. 10 C). Taken together, these
findings all implicate a direct role of Apg9p in the comple-
tion of the autophagosome/Cvt vesicle around prAPI.
Apg9p Does Not Appear to Colocalize with Any Known 
Endomembrane Markers or with Cvt and
Autophagic Vesicles 
In this study, we have also begun the characterization of
Apg9p to gain further insight into its actual function.
Apg9p is an integral membrane protein with a molecular
mass of 120–125 kD that lacks N-linked glycosyl modifica-
tions (Fig. 3). Differential centrifugation indicates that
Apg9p sediments in both low- and high-speed pellet frac-
tions, a distribution pattern that appears to be salt de-
pendent (data not shown). Sucrose gradient analysis (Fig.
4) indicates Apg9p does not appear to comigrate with
marker proteins, including Pma1p (plasma membrane),
Kex2p (Golgi complex), and ALP (vacuole). Apg9p does
share a partial overlap with the Pep12p endosome marker
(Fig. 4 B); however, due to the broad nature of the Pep12p
peak, we do not hold this result as conclusive evidence for
partial colocalization between these two proteins. In addi-
tion, sucrose density gradients indicate that Apg9p does
not appear to peak in the fractions in which prAPI-con-
taining cytoplasmic vesicles migrate (Fig. 5).
Subcellular localization of Apg9p by immunofluores-
cence microscopy and immunogold EM (Figs. 6 and 8, re-
spectively) display similar staining patterns, consisting of
one to several punctate structures proximal to the vacu-
olar membrane, but excluded from cytoplasmic auto-
phagosomes and vacuolar autophagic bodies. In vivo ex-
amination of Apg9p fused to GFP also revealed large
punctate structures that appear adjacent to the vacuolar
membrane, in agreement with the indirect in situ ob-
servations. In addition, smaller punctate structures of
Apg9pGFP could be detected throughout the cytosol (Fig.
7). This discrepancy between the in situ and in vivo obser-
vations may simply be due to differences in sensitivity
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Identifying the subcellular location of Apg9p would fa-
cilitate defining the actual function of the protein. How-
ever, we could not conclusively assign Apg9p to a known
membrane compartment. One possibility is that Apg9p is
part of the sequestering membrane of the Cvt vesicle or
the autophagosome, and that defects in Apg9p function
prevent the homotypic fusion events necessary to com-
plete vesicle formation. However, this view is problematic
because Apg9p does not cofractionate with prAPI by su-
crose gradients (Fig. 5). In addition, when Apg9pGFP-
containing punctate structures are observed in real-time
over the course of one to two hours, they remain proximal
to the vacuole and were never seen fusing with the vacuole
(data not shown). Taken together with the immunoelec-
tron microscopy data showing a lack of Apg9p-labeled
structures on autophagosomes and autophagic bodies (Fig.
8), Apg9p does not appear to be part of either the outer or
inner vesicles of the Cvt vesicle or autophagosome.
The perivacuolar localization of Apg9p by microscopy
suggests that it may be localized to an endosomal compart-
ment. The involvement of the endosome in autophagy is
also supported by other lines of evidence (Liou et al., 1997;
Shirahama et al., 1997). However, in the vps4D mutant,
which accumulates endosomal structures, and in the
apg6D/vps30D mutant, which is required for both autoph-
agy and the CPY vacuolar sorting pathway (Kametaka
et al., 1998), no change in the Apg9p labeling pattern was
detected (Fig. 6). Sucrose gradients also indicated that the
endosomal marker Pep12p does not display complete
comigration with Apg9p (Fig. 4). Nevertheless, we do not
consider these experiments to be conclusive because the
endosome represents the convergent point for multiple
routes of endomembrane traffic, and as such, may consti-
tute a heterogeneous compartment. Thus, the Pep12p-res-
ident endosome may be distinct from the endosomal com-
partment in which Apg9p is localized (Becherer et al.,
1996; Holthuis et al., 1998a,b).
Freeze fracture electron micrographs of autophago-
somes reveal a membrane surface pattern that appears dis-
tinct from other characterized yeast organelles (Baba et al.,
1995). Therefore, we postulate that the donor compart-
ment, which contributes the membranes that form the au-
tophagosome, may also be a specialized compartment.
Since Apg9p does not appear to be part of the Cvt vesicle
or autophagosomal membrane (i.e., the acceptor compart-
ment), it may be localized to this novel (undefined) donor
compartment. However, because prAPI is membrane-
associated in the apg9 mutant, it is possible that Apg9p is
localized to an accessory compartment that participates in
a later stage of the enwrapping process.
Apg9p Acts at the Rate-limiting Step in prAPI Import 
Previous kinetic analyses indicated that the rate-limiting
step in prAPI import occurs after oligomerization. The
events occurring after the formation of the double-mem-
brane vesicle may be rapid because vesicle fusion with the
vacuole and the breakdown of the Cvt and autophagic
bodies in the vacuolar lumen are rarely detected without
the aid of inhibitors or mutant strain backgrounds. Thus,
the majority of the import time may be devoted to the
membrane sequestration and vesiculation steps. The prAPI
phenotype seen in the apg9ts mutant is similar to that seen
with other apg/cvt mutant strains, including apg7D (Kim et
al., 1999). The Apg7 protein is a component of the novel
protein conjugation system required for both pathways
(Kim et al., 1999; Tanida et al., 1999). By extension, the
other components of the protein conjugation system may
also be involved in this step of the pathway, including
Apg12p, Apg5p, Apg16p, and Apg10p (Mizushima et al.,
1998, 1999; Shintani et al., 1999). Our recent finding that
Apg5p directly participates in the step of vesicle formation
supports this hypothesis (George et al., 2000). Taken to-
gether, these findings suggest that the step of vesicle for-
mation may constitute the rate-limiting step in the path-
way, requiring the concerted action of a large number of
Cvt/autophagy components, including the conjugation sys-
tem and Apg9p.
This is the first report of an integral membrane protein
directly involved in the formation of the Cvt vesicle and
autophagosome. Future analysis of the Apg9p-localized
compartment will provide a pivotal basis for investigating
the mechanism by which it directly participates in the vesi-
cle sequestration events.
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